Top Markets
#1 Nesa Nesa +789.84%
#2 Cortex Cortex +68.84%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.81%
#4 Pons Pons +32.33%
#5 QuantixAI QuantixAI +23.56%
#6 EXOD EXOD +22.78%
#7 Instadapp Instadapp +17.69%
#8 Movement Movement +15.81%
#9 OpenEden OpenEden +15.59%
#10 Magma Finance Magma Finance +13.55%
Coin of the day
Nesa Nesa
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Hangzhou Tigermed Consulting Co., Ltd Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting Co., Ltd

300347
Rang în acțiuni #3418
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
Preț acțiune
$7.37
Capitalizare de piață
$5.44B
Schimbare (1 zi)
-2.70%
Schimbare (1 an)
-19.39%
Țară
CN
Tranzacționează Hangzhou Tigermed Consulting Co., Ltd (300347)

Categorie

Healthcare
Raport P/E pentru Hangzhou Tigermed Consulting Co., Ltd (300347)
Raport P/E la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Hangzhou Tigermed Consulting Co., Ltd, raportul P/E actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/E de 0.
Istoricul raportului P/E pentru Hangzhou Tigermed Consulting Co., Ltd din 2026 până în 2026
Raportul P/E la sfârșitul fiecărui an
An Raport P/E Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raportul P/E pentru companii similare sau concurenți
Companie P/E Ratio Diferență P/E Ratio Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cum interpretezi un P/E ratio?

Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.

Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.

Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.